Top 3 ASX Companies in Promising Sectors

Whether it’s defence, healthcare, or AI-tech, companies with strong execution continue to create value for shareholders. Here’s a look at three ASX companies that are on a promising path with their latest updates and key business milestones.

Electro Optic Systems Holdings Limited (ASX: EOS)

Electro Optic Systems Holdings Limited (ASX: EOS), on 27 July 2026, published its quarterly reports for June quarter, posting a standout H1 2026 revenue of $169 million which is up by 284% YoY, an increase in record order book by 84% to $846 million since December and cash reserves of $256m, with underlying EBITDA turning positive being an indication of improved efficiency of the work.

The quarter’s biggest achievement was completing the $188m acquisition of Europe based MARSS, evolving EOS from a component supplier into a full turnkey counter-drone systems integrator and opening doors into the emerging homeland security and asset protection markets. It also landed a $175m Slinger counter-drone order from UAE-based Generation 5 and upgraded FY26 revenue guidance to $280–300m. It’s a strong comeback for a company that only a few years ago was working with the backing of debt and non-core divestments.

The company has a market capitalisation of $1.52 billion and operates in the global defence sector which is experiencing a multi-year growth driven by increased military budgets, drone proliferation and renewed great-power tensions, particularly out of the Middle East and Europe. 

Sigma Healthcare Limited (ASX: SIG)

Sigma Healthcare Limited (ASX: SIG),on 25 February 2026, released its H1 FY26 results which reported a revenue growth of 15% and normalised EBIT growth of 18.7% compared to prior corresponding period which was supported by strong integration synergies from the Chemist Warehouse merger, disciplined cost control and robust GLP-1 medicine sales.

In June 2026, SIG explored a potential acquisition of UK pharmacy chain Boots before prudently walking away in July after deciding that the deal didn’t meet its strategic and capital-return criteria. The company has also confirmed that its FY26 full year results till 30 June 2026, will be released on 27 August 2026. It’s a solid run of disciplined growth and effective capital allocation from management since the merger.

The company has a market capitalisation of $33.47 billion and operates in the Australian healthcare sector focusing on wholesale and retail pharmacy division, where its Chemist Warehouse merger has created a scaled and vertically integrated leader which benefitted from network growth, generic and GLP-1 drug volumes and also the cost synergies. 

NUIX Limited (ASX: NXL)

NUIX Limited (ASX: NXL), on 23 February 2026, released its 1H FY26 results, reporting revenue of $121 million, ACV up 8.4% to $234.4 million compared to prior corresponding period and an outstanding performance from its Nuix Neo platform, whose ACV surged 148% to $46.8 million across 101 customers. Multi-year deals rose to 33% of revenue from 22% which shows clear improvement in revenue visibility.

The other major development came from its €20 million acquisition of French graph-intelligence firm Linkurious which was first announced in December 2025 and completed in April 2026 which prompted Nuix to lift its FY26 ACV guidance range to $252–272 from $240–260 million.

It’s a genuinely solid turnaround story as the business moved from legacy eDiscovery software towards an AI-enriched, subscription-led platform, with improved profitability and a growing recurring revenue base. NXL currently carries a market capitalisation of around $401.42 million.

NXL operates in the technology sector, specifically enterprise data intelligence and investigative analytics software, an area benefiting from rising demand for AI-driven data processing and compliance tools, making it well-positioned for long-term growth.

(Source: Company Announcements)